Comparison of the clinicopathological characteristics and prognosis between Chinese patients with breast cancer with bone‑only and non‑bone‑only metastasis
- Li Zhang
- Jie Zhang
- Zhijun Li
- Yansheng Wu
- Zhongsheng Tong
Affiliations: Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, P.R. China, Department of Maxillofacial and Otorhinolaryngology Head and Neck Surgery, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, P.R. China
- Published online on: August 6, 2020 https://doi.org/10.3892/ol.2020.11953
Copyright: © Zhang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Bone is the most common site of metastatic spread in patients with breast cancer. Patients with bone‑only metastasis (BOM) are a unique group. The aim of the present study was to compare the clinicopathological characteristics, survival and prognostic factors of patients with BOM and non‑BOM. The clinical data of 1,290 patients with metastatic breast cancer treated at the Tianjin Medical University Cancer Institute and Hospital (Tianjin, China) between January 2008 and December 2017 were reviewed. The clinical data were divided into a BOM group (n=208 cases) and a non‑BOM group (n=1,082 cases). Patients with BOM had longer disease‑free survival, progression‑free survival (PFS) and overall survival (OS) compared with patients in the non‑BOM group. The hormone receptor (HR) status and number of metastases were significant influencing factors of PFS in the BOM group. Furthermore, the HR status, location of bone metastasis and number of bone metastases were significantly associated with OS of patients in the BOM group. Age at diagnosis of metastasis, HR status and tumor stage were significantly associated with OS in the non‑BOM group. In the BOM group, patients with HR+/human epidermal growth factor receptor 2 (HER2)‑ tumors had the most favorable prognosis. In the non‑BOM group, patients with HR+/HER2‑ and HER2+ tumors had improved prognosis. In the BOM with HR+/HER2‑ subgroup, the PFS and OS of patients receiving endocrine therapy or sequential therapy (chemotherapy followed by endocrine therapy) was significantly improved compared with those receiving chemotherapy alone (P<0.05). Skeletal‑related events were significantly associated with the number of bone metastases (P<0.001). The most common secondary metastatic site in the BOM group was the liver. The prognosis of the patients in the BOM group was improved compared with that in the non‑BOM patients. HR‑ and multiple bone metastases, as well as combined axial and appendicular bone metastases, were significantly associated with poor prognosis in the patients with BOM. For patients in the HR+/HER2‑ BOM subgroup, endocrine therapy alone resulted in satisfactory results.